Company intelligence
Ksilink
Patient-based drug discovery
Biotechnology Research
Strasbourg, FR
13 employees
Founded 2014
2 public signals
About Ksilink
We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Verified activity
Signals from Ksilink
2 published signals
Products & Services
Ksilink presented its lead program for a first-in-class small molecule disease modifying therapy for Parkinson's Disease enabled by patient-based phenotypic screening.
Reported by Mona Boyé
Capital & Finance
Ksilink is currently establishing an investible NewCo to advance its lead program for a first-in-class small molecule disease modifying therapy for Parkinson's Disease with expected clinical entry as early as 2028.
Reported by Mona Boyé